Tacrolimus Magnetic Beads (High Specificity)

Product Description

Tacrolimus Magnetic Beads (High Specificity)
Catalog number: B2010391
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 1 mL
Molecular Weight or Concentration: 0.1% solid suspension
Supplied as: Liquid Suspension
Appearance: Dark Brown suspension
Applications: high quality suspension of magnetic particles (~1 um) conjugated to Tacrolimus. Highly specific and highly stable, these particles can be used for easy one-step capture various antigens, proteins and antibodies specific to Tacrolimus. These particles can be recovered easily using a magnet, allowing for various applications such as purification, depletion, assay development and more.
Storage: 2-8°C
Keywords: Tacrolimus magnetic particles, magnetic particles conjugates to Tacrolimus, FK506 magnetic particles
Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Complete Tacrolimus Product Line

Download Brochure

References:
1: Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, Pharmacodynamics and
Pharmacogenetics of Tacrolimus in Kidney Transplantation. Curr Drug Metab.
2018;19(6):513-522.

2: Pennington CA, Park JM. Sublingual tacrolimus as an alternative to oral
administration for solid organ transplant recipients. Am J Health Syst Pharm.
2015 Feb 15;72(4):277-84.

3: Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of
tacrolimus in solid organ transplantation. Clin Pharmacokinet.
2004;43(10):623-53.

4: Jouve T, Noble J, Rostaing L, Malvezzi P. An update on the safety of
tacrolimus in kidney transplant recipients, with a focus on tacrolimus
minimization. Expert Opin Drug Saf. 2019 Apr;18(4):285-294.

5: Huang X, Xu B. Efficacy and Safety of Tacrolimus versus Pimecrolimus for the
Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis.
Dermatology. 2015;231(1):41-9.

6: Degraeve AL, Moudio S, Haufroid V, Chaib Eddour D, Mourad M, Bindels LB,
Elens L. Predictors of tacrolimus pharmacokinetic variability: current evidences
and future perspectives. Expert Opin Drug Metab Toxicol. 2020 Sep;16(9):769-782.

7: Kalt DA. Tacrolimus: A Review of Laboratory Detection Methods and Indications
for Use. Lab Med. 2017 Nov 8;48(4):e62-e65. doi: 10.1093/labmed/lmx056. PMID:
29096030.

8: Zhang X, Lin G, Tan L, Li J. Current progress of tacrolimus dosing in solid
organ transplant recipients: Pharmacogenetic considerations. Biomed
Pharmacother. 2018 Jun;102:107-114.

9: Kim YH, Shin HY, Kim SM. Long-Term Safety and Efficacy of Tacrolimus in
Myasthenia Gravis. Yonsei Med J. 2019 Jul;60(7):633-639.
10: Tremblay S, Alloway RR. Clinical Evaluation of Modified Release and
Immediate Release Tacrolimus Formulations. AAPS J. 2017 Sep;19(5):1332-1347.

Products Related to Tacrolimus Magnetic Beads Conjugate : Beads and Particles